

EXHIBIT B

Initials: DEB/EWM/cmm Docket No.: 3028.1000-000 Date: May 23, 2001

This is to acknowledge receipt of the following documents each filed under Certificate of Mailing Procedure 37 C.F.R. 1.8:

☒ INFORMATION DISCLOSURE STATEMENT _____ w/copy
☒ Form PTO-1449 pp 3 _____ x _____ with references as noted in 1449
____ Check for \$ _____
____ Authorization to Charge all Fees _____
____ Other _____

Applicant(s): Guy A. Rouleau, *et al.*
Application No.: 09/590,211

Filed: June 8, 2000

Title: SHORT GCG EXPANSIONS IN THE PAB II GENE/ FOR
OCULOPHARYNGEAL MUSCULAR DYSTROPHY AND
DIAGNOSTIC THEREOF

Date received by the PTO:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Guy A. Rouleau and Bernard Brais

Application No.: 09/590,211 Group Art Unit: 1632

Filed: June 8, 2000 Examiner:

Title: SHORT GCG EXPANSIONS IN THE PAB II GENE FOR
OCULOPHARYNGEAL MUSCULAR DYSTROPHY AND DIAGNOSTIC
THEREOF

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on 5/23/01	<i>Christina McSweeney</i>
Date	Signature
Christina M. McSweeney	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
- ☐ the explanation provided in the Specification.
- ☐ submission of the enclosed International Search Report.
- ☐ the enclosed English language abstract.
- ☐ Applicant requests that the following pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,


HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

David E. Brook R.N. 22,592

By *for Elizabeth W. Mata*
Elizabeth W. Mata
Registration No.: 38,236
Telephone: (781) 861-6240
Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *5/23/01*

PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. 3028.1000-000		APPLICATION NO. 09/590,211	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 23, 2001 (Use several sheets if necessary)				APPLICANT Guy A. Rouleau and Bernard Brais			
				FILING DATE June 8, 2000		GROUP 1632	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
7W	AL	WO98/31800	23 JUL 98	PCT			
7W	AM	WO99/29896	17 JUN 99	PCT			
	AN						
	AO						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
7W	AR	Akarsu, A.N., et al., "Genomic Structure of HOXD13 Gene: A Nine Polyalanine Duplication Causes Synpolydactyly in Two Unrelated Families," <i>Human Molecular Genetics</i> , 5(7): 945-952 (1996).					
	AS	Bienroth, S, et al., "Assembly of a Processive Messenger RNA Polyadenylation Complex," <i>The EMBO Journal</i> , 12(2): 585-594 (1993).					
	AT	Brais, B., et al., "Using the Full Power of Linkage Analysis in 11 French Canadian Families to Fine Map the Oculopharyngeal Muscular Dystrophy Gene," <i>Neuromuscular Disorder</i> 7(1):S70-S74 (1997).					
	AU	Brais, B, et al., "The Oculopharyngeal Muscular Dystrophy Locus Maps to the Region of the Cardiac α and β Myosin Heavy Chain Genes on Chromosome 14q11.2-q13," <i>Human Molecular Genetics</i> , 4(3): 429-434 (1995).					
	AV	Davies, S.W., "Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation," <i>Cell</i> , 90:537-548 (1997).					
	AW	DiFiglia, M, et al., "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain," <i>Science</i> , 277: 1990-1993 (1997).					
	AX	Evans, G.A, et al., "High Efficiency Vectors for Cosmid Microcloning and Genomic Analysis," <i>Gene</i> , 79:9-20 (1989).					
	AY	Forood, B., et al., "Formation of an Extremely Stable Polyalanine β -Sheet Macromolecule," <i>Biochem. And Biophysical Res. Communications</i> , 211(1): 7-13 (1995).					
	AZ	Krause, S., et al., "Immunodetection of Poly(A) Binding Protein II in the Cell Nucleus," <i>Experimental Cell Res.</i> , 214: 75-82 (1994).					
EXAMINER				DATE CONSIDERED			
				12/5/02			

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3028.1000-000APPLICATION NO.
09/590,211INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

May 23, 2001

(Use several sheets if necessary)

APPLICANT
Guy A. Rouleau and Bernard BraisFILING DATE
June 8, 2000GROUP
1632

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

9u	AR2	Mundlos, S., et al., "Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia," <i>Cell</i> , 89: 773-779 (1997).
	AS2	Editorials, "DNA-Triplet Repeats and Neurologic Disease," <i>The New England Journal of Med.</i> , 335(16): 1222-1224 (1996).
	AT2	Scherzinger, E., et al, "Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-Like Protein Aggregates In Vitro and In Vivo," <i>Cell</i> 90: 549-558 (1997).
	AU2	Tome, M.S., et al., "Nuclear Inclusions in Oculopharyngeal Dystrophy," <i>Act Neuropathol.</i> 49: 85-87 (1980).
	AV2	Muragaki, Y., et al., "Polyalanine Expansion in Synpolydactyly Might Result from Unequal Crossing-Over of HOXD13," <i>Science</i> 275: 406
	AW2	Wells, R.D., "Molecular Basis of Genetic Instability of Triplet Repeats," <i>The Journal of Biological Chem.</i> 271(6): 2875-2878 (1996).
	AX2	Wahle, E., et al., "Mammalian Poly(A)-Binding Protein II," <i>J. of Biological Chem.</i> , 268(4): 2937-2945 (1993).
	AY2	Wahle E., "A Novel Poly(A)-Binding Protein Acts As a Specificity Factor in the Second Phase of Messenger RNA Polyadenylation," <i>Cell</i> , 66: 759-768 (1991).
	AZ2	Nemeth, A., et al., "Isolation of Genomic and cDNA Clones Encoding Bovine Poly(A) Binding Protein II," <i>Nucleic Acids Res.</i> , 23(20): 4034-4041 (1995).
	AR3	Riggins, G.J., et al. "Human Genes Containing Polymorphic Trinucleotide Repeats," <i>Nat Genet</i> , 2(3):186-191 (1992).
	AS3	Brais, B., et al., "Short GCG Expansions in the PABP2 Gene Cause Oculopharyngeal Muscular Dystrophy," <i>Nature Genetics</i> 18: 164-167 (1998).

EXAMINER



DATE CONSIDERED

12/5/02

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
3028.1000-000APPLICATION NO.
09/590,211INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

May 23, 2001

(Use several sheets if necessary)

APPLICANT

Guy A. Rouleau and Bernard Brais

FILING DATE
June 8, 2000GROUP
1632

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

96	AT3	Lamartine, J. et al., "Cloning Sequencing and Chromosomal Assignment of a New cDNA Clone to Xq12-q13 and 14q11," EMBL Data Base Accession Number U12206 (1995).
	AU3	"National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index," EMBL Data Base Accession Number AA618589 (1997).
	AV3	Sullivan, T.B.T., et al., "Oculopharyngeal Muscular Dystrophy (OPMD) - Report and Genetic Studies of an Australian Kindred," <i>Clinical Genetics</i> , 51: 52-55 (1997).
	AW3	Bouchard, J.P. et al., "A Simple Test for the Detection of Dysphagia in Members of Families with Oculopharyngeal Muscular Dystrophy (OPMD)," <i>Can.J. Neurol. Sci.</i> 19(2):296-297 (1992).

EXAMINER

Joe Watson

DATE CONSIDERED

12/5/02